The U.S. Food and Drug Administration granted enVVeno Medical Corporation a first‑ever Investigational Device Exemption on April 29, 2026, allowing the company to begin enrollment in a U.S. pivotal study of its non‑surgical replacement venous valve, the enVVe system.
The enVVe system targets severe deep chronic venous insufficiency (CVI), a condition that affects an estimated 3 million U.S. patients. The IDE removes a major regulatory hurdle and positions enVVeno to collect the clinical data needed to support future regulatory submissions and potential market approval.
The TAVVE pivotal trial is structured in two stages: an initial 10‑patient safety cohort followed by a 220‑patient randomized phase (165 patients receiving enVVe and 55 controls). The company could file for FDA post‑marketing approval one year after the 220th second‑stage patient is enrolled, outlining a clear path toward commercialization.
Financially, enVVeno reported approximately $25 million in cash and investments as of March 31, 2026. This balance is projected to fund operations through the third quarter of 2027, providing the runway necessary to execute the TAVVE trial and advance the product pipeline.
CEO Robert Berman said the company has worked closely with the FDA to design the TAVVE study to meet regulatory expectations and expressed enthusiasm about activating clinical sites. The approval de‑risks the product and strengthens enVVeno’s position in the emerging venous valve market.
Prior to this milestone, enVVeno had faced an unfavorable appeal decision for its VenoValve surgical device. The new IDE marks a significant turnaround, and the company has recently regained Nasdaq compliance by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days from January 20 through February 2, 2026. The approval opens a multi‑billion‑dollar market opportunity for a minimally invasive solution to severe CVI.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.